| Identification | Back Directory | [Name]
Bendamustine | [CAS]
16506-27-7 | [Synonyms]
Bendamustine
4-(5-(Bis(2-chloroethyl)
-1-methyl-1H-benzo[d]imidazol-2-yl)
5-(Bis(2-chloroethyl)amino)-1-methyl-2-benzimidazolebutyric acid
5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid
4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid
1H-BenziMidazole-2-butanoicacid, 5-[bis(2-chloroethyl)aMino]-1-Methyl-
4-(5-(bis(2-chloroethyl)aMino)-1-Methyl-1H-benzo[d]iMidazol-2-yl)butanoic acid | [Molecular Formula]
C16H21Cl2N3O2 | [MDL Number]
MFCD00866481 | [MOL File]
16506-27-7.mol | [Molecular Weight]
358.26 |
| Chemical Properties | Back Directory | [Boiling point ]
585.2±50.0 °C(Predicted) | [density ]
1.31±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C, protect from light | [solubility ]
DMSO : 100 mg/mL (279.13 mM; Need ultrasonic) | [pka]
4.50±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
Treatment of
hematologic cancer, especially non-Hodgkin’s lymphoma. | [Definition]
ChEBI: Bendamustine is a member of benzimidazoles. | [Brand name]
Ribomustine (Amcis AG, Switzerland). | [Enzyme inhibitor]
This nitrogen mustard and anticancer drug (FWfree-acid = 358.26 g/mol; CAS 16506-27-7), also known by its code name SDX-105, its trade names Treanda?, Treakisym?, Ribomustin?, and Levact?, as well as by its systematic name 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2- yl]butanoic acid, is a relatively nonspecific DNA alkylating agent that causes intra- and inter-strand cross-links. Bendamustine is used in the treatment of chronic lymphocytic leukemia (CLL), Hodgkin’s disease, nonHodgkin’s lymphoma, multiple myeloma and lung cancer. Pharmacokinetics: After intravenous infusion, >95% of the drug becomes protein-bound, mainly to albumin; however, only free bendamustine is active. Bendamustine is metabolized by liver cytochrome p450, and elimination (renal) is biphasic, with an initial half-life of 6–10 minutes and a terminal half-life of approximately 30 minutes. |
|
|